Everything below concerns Cardarine. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
=== Synthesis === To synthesize dexamethasone, 16β-methylprednisolone acetate is dehydrated to the 9,11-dehydro derivative. This is then reacted with a source of hypobromite, such as basic N-bromosuccinimide, to form the 9α-bromo-11β-hydrin derivative, which is then ring-closed to an epoxide. A ring-opening reaction with hydrogen fluoride in tetrahydrofuran gives dexamethasone.
Subsequent studies in 1995 confirmed that the db gene encodes the leptin receptor, and that it is expressed in the hypothalamus, a region of the brain known to regulate the sensation of hunger and body weight.
=== DDM === Direct Drive Monitor (DDM) 1.0 standard was approved in December 2008. It allows for controller-less monitors where the display panel is directly driven by the DisplayPort signal, although the available resolutions and color depth are limited to two-lane operation.
Sources: en.wikipedia.org
== Sources == Joan E. Howard, From Violence to Vision: Sacrifice in the Works of Marguerite Yourcenar (1992) Josyane Savigneau, Marguerite Yourcenar: Inventing a Life (1993). George Rousseau, Marguerite Yourcenar: A Biography (London: Haus Publishing, 2004). Judith Holland Sarnecki, Subversive Subjects: Reading Marguerite Yourcenar (2004) Giorgetto Giorgi, "Il Grand Tour e la scoperta dell’antico nel Labyrinthe du monde di Marguerite Yourcenar," in Sergio Audano, Giovanni Cipriani (ed.), Aspetti della Fortuna dell'Antico nella Cultura Europea: atti della settima giornata di studi, Sestri Levante, 19 March 2010 (Foggia: Edizioni il Castello, 2011) (Echo, 1), 99–108. Les yeux ouverts, entretiens avec Mathieu Galey (Éditions du Centurion « Les interviews », 1980). Bérengère Deprez, Marguerite Yourcenar et les États-Unis. Du nageur à la vague, Éditions Racine, 2012, 192 p. Bérengère Deprez, Marguerite Yourcenar and the United States. From Prophecy to Protest, Peter Lang, coll. « Yourcenar », 2009, 180 p. Deprez, Marguerite Yourcenar. Écriture, maternité, démiurgie, essai, Bruxelles, Archives et musée de la littérature/PIE-Peter Lang, coll. « Documents pour l’histoire des francophonies », 2003, 330 p. Donata Spadaro, Marguerite Yourcenar et l'écriture autobiographique : Le Labyrinthe du monde, bull. SIEY, no 17, décembre 1996, p. 69 à 83 Donata Spadaro, Marguerite Yourcenar e l'autobiografia (ADP, 2014) Mireille Brémond, Marguerite Yourcenar, une femme à l'Académie (Garnier, 2019);. Rémy Poignault, L'Antiquité dans l'œuvre de Marguerite Yourcenar.
== Microorganisms == In bacteria and fungi, the sulfur assimilation pathway is similar to that in plants, where inorganic sulfate is reduced to sulfide, and then incorporated into cysteine and other sulfur-containing compounds. Bacteria and fungi can absorb inorganic sulfate from the environment through a sulfate transporter, which is regulated by the presence of sulfate in the medium. Once inside the cell, sulfate is activated by ATP sulfurylase to form adenosine 5'-phosphosulfate (APS), which is then reduced to sulfite by APS reductase. Sulfite is further reduced to sulfide by sulfite reductase, which is then incorporated into cysteine by enzyme. Cysteine, once synthesized, can be used for the biosynthesis of methionine and other important biomolecules. In addition, microorganisms also use sulfur-containing compounds for various other purposes, such as the synthesis of antibiotics. Sulfur assimilation in microorganisms is regulated by a variety of environmental factors, including the availability of sulfur in the medium and the presence of other nutrients. The activity of key enzymes in the sulfur assimilation pathway is also regulated by feedback inhibition from downstream products, similar to the regulation seen in plants.
=== Cognitive impairment === Some people receiving chemotherapy report fatigue or non-specific neurocognitive problems, such as an inability to concentrate; this is sometimes called post-chemotherapy cognitive impairment, referred to as "chemo brain" in popular and social media.
Use of DART compared to traditional methods minimizes sample amount, sample preparation, eliminates extraction steps, decreases limit of detection and analysis time. Also it provides a broad range sensitivity, simultaneous determination of multi-drug analytes and sufficient mass accuracy for formulation determination. The DART ion source is a kind of gas-phase ionization, and it requires some sort of volatility of the analyte to support thermally assisted desorption of analyte ions. This limits the size range of the molecules that can be analyzed by DART i.e. m/z 50 to 1200. DART-MS is capable of semi-quantitative and quantitative analysis. To accelerate sample release from the surface, the DART gas stream is usually heated to temperature in the range 100-500 °C and this operation can be employed for temperature-dependent analysis.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.